CB-010
CB-010 is an allogeneic (off-the-shelf) CAR-T cell therapy developed by Caribou Biosciences for relapsed or refractory B-cell non-Hodgkin lymphoma. Using Caribou's chRDNA gene-editing platform, donor T cells are engineered to express a CD19-targeting chimeric antigen receptor and edited to reduce immune markers that would trigger rejection in a different patient, enabling a single manufacturing run to supply multiple patients. Unlike autologous CAR-T therapies (Yescarta, Breyanzi), which require 3–4 weeks of custom manufacturing per patient, CB-010 is available immediately as a stockpiled product; Phase 1 dose-expansion data are being presented in 2026.
Upcoming catalysts
Programs
B-cell Non-Hodgkin Lymphoma
Relapsed or refractory large B-cell lymphoma carries a poor prognosis; approved autologous CAR-T therapies (Yescarta, Breyanzi) achieve complete responses in ~30–40% of patients but require 3–4 weeks of custom manufacturing per patient, limiting access for rapidly progressing disease. CB-010 aims to match efficacy as an off-the-shelf product available immediately; Phase 1 dose-expansion data tracking CR rate, durability past 6 months, and CRS/ICANS incidence are being presented in 2026.